Benefit From Anti-EGFRs in RAS and BRAF Wild-Type Metastatic Transverse Colon Cancer: A Clinical and Molecular Proof of Concept Study
ESMO Open - United Kingdom
doi 10.1136/esmoopen-2019-000489
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2019
Authors
Publisher
BMJ